Home>>Signaling Pathways>> Microbiology & Virology>> SRPK>>SPHINX

SPHINX

Catalog No.GC65981

SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD.

Products are for research use only. Not for human use. We do not sell to patients.

SPHINX Chemical Structure

Cas No.: 848057-98-7

Size Price Stock Qty
10mM (n 1mL DMSO)
$277.00
In stock
5mg
$252.00
In stock
10mg
$378.00
In stock
25mg
$702.00
In stock
50mg
$1,125.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IC50: 0.58 μM (SRPK1)[1]

SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD[1].

SPHINX (10 μM; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2[1].
SPHINX (5 μM; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].

Western Blot Analysis[1]

Cell Line: ARPE-19 cell line
Concentration: 10 μM
Incubation Time: 2 hours
Result: Blocked EGF-induced phosphorylation of SRSF1 and SRSF2.

SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo[1].
SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats[1].

Animal Model: C57/B6 mice with laser-induced CNV[1]
Dosage: 10 ng
Administration: Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7
Result: Significantly reduced neovascular growth compared with saline-injected controls.
Animal Model: Norway Brown rats with laser-induced choroidal neovascularization[1]
Dosage: 25 ng (10 ng/uL)
Administration: Intraocular injection; 25 ng (10 ng/uL) on laser photocoagulation day 0 and day 7
Result: Significantly reduced the CNV area compared with saline injected controls.

Reviews

Review for SPHINX

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SPHINX

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.